 |
22 Diseases |  |
0 Trials |
|
0 Trials |  |
97 News |  |
| «12 |
- ||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion: Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects (clinicaltrials.gov) - Oct 3, 2013
P1, N=60, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
Active, not recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial initiation date: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Jul 25, 2013
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Initiation date: Feb 2013 --> Jun 2013
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Jul 25, 2013
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Initiation date: Feb 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- ||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P2 trial: Safety and Efficacy of MT-4666 (clinicaltrials.gov) - Jan 7, 2013
P2, N=450, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Nov 12, 2012
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Nov 12, 2012
P3, N=700, Recruiting, Sponsor: EnVivo Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 28, 2012
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- |||||||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 24, 2012
P3, N=700, Recruiting, Sponsor: EnVivo Pharmaceuticals, Inc.
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 24, 2012
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence (clinicaltrials.gov) - Apr 19, 2012
P2, N=450, Recruiting, Sponsor: A. Eden Evins
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion: Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Mar 29, 2012
P2, N=409, Completed, Sponsor: FORUM Pharmaceuticals Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P1 trial, Monotherapy: Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia (clinicaltrials.gov) - Mar 13, 2012
P1, N=21, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
- ||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P1 trial: Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects (clinicaltrials.gov) - Dec 5, 2011
P1, N=60, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P2 trial: A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence (clinicaltrials.gov) - Nov 24, 2011
P2, N=450, Recruiting, Sponsor: A. Eden Evins